Can I Take Vitamin B12 with Synthroid (Levothyroxine)? A Women's Guide

The short answer: B12 and Synthroid do not directly interact

There is no known pharmacokinetic or pharmacodynamic interaction between vitamin B12 (cobalamin) and levothyroxine. B12 does not bind levothyroxine in the gut, does not induce or inhibit the enzymes that convert T4 to T3, and does not alter thyroid-stimulating hormone (TSH) signaling. The FDA prescribing information for levothyroxine lists calcium carbonate, ferrous sulfate, antacids, and several other compounds as absorption inhibitors, but B12 is not among them.

"no direct interaction" is not the same as "nothing to watch." Women on levothyroxine carry a meaningfully higher burden of B12 deficiency than the general population, and the reasons are clinical, not coincidental.

Why B12 deficiency is more common in women with hypothyroidism

Autoimmune hypothyroidism (Hashimoto thyroiditis) is the most common cause of hypothyroidism in the United States, affecting roughly 14 million women. Hashimoto disease co-occurs with other autoimmune conditions at elevated rates, and pernicious anemia, the autoimmune destruction of gastric parietal cells that produce intrinsic factor, is one of them. Without intrinsic factor, dietary B12 from food cannot be absorbed in the terminal ileum.

A 2021 study in the Journal of Clinical Endocrinology and Metabolism found that autoimmune thyroid disease patients had significantly higher rates of pernicious anemia than age-matched controls, with women bearing the larger share of that burden. The takeaway: if you have Hashimoto disease, your doctor should screen for B12 deficiency, not assume that your diet covers it.

Atrophic gastritis and low stomach acid

Hypothyroidism itself slows gastric motility and can reduce gastric acid secretion. This matters because B12 from food must be cleaved from food proteins by stomach acid before intrinsic factor can bind it. Low acid means less food-bound B12 absorbed, even if your intrinsic factor is intact. Crystalline B12 in supplements bypasses this step entirely, which is one reason supplemental B12 works when dietary B12 does not.

How levothyroxine absorption actually works (and what truly disrupts it)

Levothyroxine is absorbed primarily in the jejunum and ileum. Peak absorption under fasting conditions is approximately 70-80% of the oral dose. Anything that raises gastric pH, binds the drug in the gut lumen, or speeds transit reduces that number.

The evidence-based list of problematic co-ingestions includes:

| Substance | Estimated absorption reduction | Recommended separation | |---|---|---| | Calcium carbonate | Up to 40% | 4 hours | | Ferrous sulfate | Up to 9% decrease in T4 | 4 hours | | Proton pump inhibitors | Modest but clinically relevant | Take levo on empty stomach | | Calcium-fortified orange juice | ~17% reduction | 4 hours | | Soy formula / high-fiber meals | Variable | 4 hours | | Vitamin B12 | No documented interaction | No separation required |

Sources: FDA levothyroxine prescribing information and Singh et al., Thyroid, 2023.

The standard clinical instruction is to take levothyroxine on an empty stomach, 30-60 minutes before breakfast or other medications. This protects against the many things that do interfere, even if B12 is not one of them.

A practical morning routine

Plenty of women take a B12 supplement at breakfast, which is fine from an interaction standpoint. Swallow your levothyroxine with water when you wake up. Have breakfast 30-60 minutes later, and take your B12 with that meal if you prefer food in your stomach for tolerability. No special separation beyond the usual levothyroxine window is needed.

The metformin connection: where B12 depletion becomes a real concern

This is where the clinical picture gets more complicated for many women with hypothyroidism. Metformin is frequently co-prescribed in women who have:

• Type 2 diabetes alongside hypothyroidism
• Polycystic ovary syndrome (PCOS) with insulin resistance
• Obesity-related metabolic disease managed with GLP-1 agonists plus adjunct metformin

Metformin competitively inhibits a calcium-dependent ileal membrane transporter that the intrinsic factor-B12 complex needs to enter the bloodstream. Long-term metformin use reduces serum B12 levels in 20-30% of users, with risk rising with dose and duration. The landmark CPIC and American Diabetes Association guidance now recommends periodic B12 monitoring in all long-term metformin users.

If you are a woman taking both levothyroxine and metformin, B12 deficiency becomes a two-vector risk: impaired absorption from possible pernicious anemia or low acid production from autoimmune thyroid disease, plus metformin's transporter inhibition. Neither drug interacts with the other, but the combination creates a physiological environment where B12 depletion is more likely.

Neurological consequences that matter for women

B12 deficiency causes subacute combined degeneration of the spinal cord, peripheral neuropathy, and cognitive changes. These are the same symptoms women often attribute to menopause-related brain fog or hypothyroid fatigue. A 2023 cross-sectional study in Nutrients found that women with undiagnosed B12 deficiency were significantly more likely to have their neurological symptoms attributed to menopause or thyroid disease rather than B12, delaying correct treatment by a median of 18 months.

The diagnostic overlap is real. Fatigue, poor concentration, cold intolerance, and tingling in the extremities appear in hypothyroidism, menopause, and B12 deficiency. Getting serum B12 and methylmalonic acid (MMA) tested when TSH is being checked costs little and prevents misattribution.

Vitamin B12 across the female life stages

Reproductive years and PCOS

Women of reproductive age with hypothyroidism are often also managing PCOS, particularly if insulin resistance is present. Metformin is a first-line treatment for PCOS-related metabolic dysfunction. ASRM practice guidelines recommend metformin for ovulation induction in women with PCOS who have not responded to lifestyle modification, but they do not specifically flag B12 monitoring, a gap clinicians should address proactively.

If you have PCOS, are on metformin, and are also managing hypothyroidism with levothyroxine, a baseline serum B12 plus MMA before starting metformin and annual monitoring thereafter is a reasonable standard of care.

Trying to conceive

Thyroid disease and fertility are tightly linked. Subclinical hypothyroidism affects an estimated 2-3% of women of reproductive age and is associated with increased miscarriage risk. ACOG Practice Bulletin 223 recommends TSH screening in women with symptoms or risk factors before conception.

B12 is not directly required for thyroid hormone synthesis, but deficiency during the periconceptional period is independently associated with neural tube defects and early pregnancy loss. A woman optimizing for conception should have adequate B12 alongside adequate folate. The recommended B12 intake during pregnancy is 2.6 mcg per day, compared with 2.4 mcg in non-pregnant adults. Women with pernicious anemia or malabsorption need supplemental or intramuscular B12 regardless of pregnancy status.

Pregnancy and lactation

Pregnancy safety of vitamin B12: B12 is a water-soluble vitamin with no documented teratogenicity at physiologic or supplemental doses. It is not assigned a formal FDA pregnancy category under the current labeling system, but the safety profile is well established. Most prenatal vitamins contain cyanocobalamin or methylcobalamin at doses of 6-12 mcg, and high-dose oral B12 (1,000 mcg daily) has been used safely in pregnancy for pernicious anemia.

Levothyroxine in pregnancy: Levothyroxine is the standard treatment for hypothyroidism during pregnancy and is considered safe. The dose typically needs to increase by 25-50 mcg in the first trimester because pregnancy raises TBG (thyroxine-binding globulin), reducing free T4 availability. ACOG recommends checking TSH every 4 weeks through mid-pregnancy and at least once at 26-32 weeks. There is no interaction between levothyroxine and B12 supplementation in pregnancy.

Lactation: B12 transfers into breast milk, and breast milk B12 directly reflects maternal serum levels. Women who are vegan, have pernicious anemia, or have had gastric surgery should supplement to protect infant neurological development. The NIH Office of Dietary Supplements notes that the AI for lactating women is 2.8 mcg per day, and postnatal depletion is a recognized risk when maternal stores are borderline. Levothyroxine transfers minimally into breast milk and is not contraindicated during breastfeeding.

Perimenopause

The perimenopausal window creates a convergence of thyroid, B12, and estrogen-related changes that clinicians rarely address as a system. Here is a framework for thinking through it:

The perimenopausal thyroid-B12 overlap: Estrogen fluctuation during perimenopause alters thyroid-binding globulin, which can shift TSH interpretation. At the same time, gastric acid secretion tends to decline with age, worsening food-bound B12 absorption independent of autoimmune disease. Women entering perimenopause who have been stable on a levothyroxine dose may need a dose adjustment, not because levothyroxine changed, but because TBG dynamics shifted.

Perimenopausal women on levothyroxine should have TSH checked annually and B12 checked at least every two years, or more frequently if they are on metformin, use proton pump inhibitors, or follow a plant-heavy diet.

Brain fog disambiguation: Cognitive changes during perimenopause overlap with those from B12 deficiency and undertreated hypothyroidism. A TSH, free T4, and B12 panel (with MMA if B12 is borderline, meaning 150-300 pg/mL) is the minimum workup before attributing perimenopausal cognitive symptoms to hormone fluctuation alone.

Post-menopause

Postmenopausal women have the highest B12 deficiency risk in any adult age group outside the elderly. Gastric atrophy, reduced intrinsic factor, and long-term PPI use all compound over decades. A NHANES analysis found that approximately 6% of adults over 60 are frankly B12 deficient, and a further 20% are in the marginal range. Postmenopausal women on long-term levothyroxine who develop new fatigue, neuropathy, or cognitive changes need B12 evaluated before assuming the thyroid dose is wrong.

Who should consider B12 supplementation alongside levothyroxine

Not every woman on Synthroid needs a B12 supplement. The decision should be based on risk factors, not routine.

Higher-priority candidates for B12 supplementation or monitoring:

• Women with Hashimoto thyroiditis who also have other autoimmune conditions
• Women taking metformin (PCOS, diabetes, adjunct weight-loss therapy)
• Vegetarians and vegans (animal products are the primary dietary B12 source)
• Women over 50, given declining gastric acid and intrinsic factor
• Women who use proton pump inhibitors chronically
• Women who have had bariatric surgery or gastric bypass
• Pregnant women with borderline B12 levels

Lower-priority candidates (supplementation may not be needed):

• Young women with no autoimmune history, no metformin, and omnivorous diet
• Women with confirmed normal serum B12 and MMA within the past year
• Women who already take a prenatal or multivitamin containing adequate B12

Forms and doses of vitamin B12: does the type matter?

B12 comes in three main supplemental forms: cyanocobalamin, methylcobalamin, and hydroxocobalamin. The evidence does not clearly favor one form over another for most women. A 2022 systematic review in Nutrients found that methylcobalamin and cyanocobalamin produced equivalent increases in serum B12 in deficient adults, though absorption kinetics differ slightly.

For women with MTHFR variants, some clinicians prefer methylcobalamin on the rationale that it skips one metabolic conversion step. The evidence supporting this preference over cyanocobalamin in clinical outcomes is thin; it is an area where the data in women specifically is sparse, and current practice is largely extrapolated from general-population studies.

Typical supplemental doses:

• Maintenance / dietary gap fill: 25-100 mcg daily
• Metformin-related depletion prevention: 250-1,000 mcg daily (some guidelines suggest 1,000 mcg daily for confirmed deficiency)
• Pernicious anemia (oral high-dose protocol): 1,000-2,000 mcg daily; this is an alternative to monthly IM injections in adherent patients, supported by Cochrane evidence
• Pregnancy/lactation with confirmed deficiency: 1,000 mcg daily or as directed by the prescribing clinician

Monitoring: what to ask your clinician to check

TSH alone is not enough when you are managing hypothyroidism and have B12 risk factors. Ask your provider for:

1. Serum B12. A level below 200 pg/mL is frankly deficient. Levels between 200 and 300 pg/mL are borderline and warrant MMA testing.
2. Methylmalonic acid (MMA). Elevated MMA confirms functional B12 deficiency even when serum B12 is in the lower-normal range. This is the more sensitive test and is particularly useful in older women or those with neurological symptoms.
3. Complete blood count (CBC). Macrocytic anemia (elevated MCV) is a late-stage sign of B12 deficiency; its absence does not rule out deficiency.
4. Homocysteine. Elevated homocysteine occurs with both B12 and folate deficiency and carries independent cardiovascular risk in women.
5. Anti-parietal cell and anti-intrinsic factor antibodies if pernicious anemia is suspected.

The American Thyroid Association notes that women with autoimmune thyroid disease have a 2-5 times higher risk of other autoimmune conditions, making pernicious anemia screening more than an afterthought.

A note on the evidence gap

Women have been consistently underrepresented in trials examining nutrient-drug interactions and thyroid pharmacokinetics. Most of the levothyroxine absorption data comes from studies that either did not stratify by sex or enrolled predominantly male or postmenopausal female populations. The specific interaction data for B12 and levothyroxine is extrapolated from absence of known pharmacokinetic interaction, not from a dedicated women-focused trial. That absence of evidence is reassuring, but it is not the same as a large randomized controlled trial confirming safety in premenopausal, pregnant, or perimenopausal women specifically. Clinicians should apply individualized judgment, and women should feel free to ask their prescribers directly whether their specific combination of supplements, life stage, and comorbidities has been addressed in the research they are citing.